News
Encouraging news for treatment targeting retinitis pigmentosa
THE STEM CELLAR The Official Blog of CIRM, California’s Stem Cell Agency JULY 29, 2020 / KEVIN MCCORMACK While most people probably wouldn’t put 2020 in their […]
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Foundation Fighting Blindness EYE ON THE CURE RESEARCH NEWS – JUL 27, 2020 The emerging therapy is designed to work independent of the mutated gene […]
Can progenitor cells go further than gene therapy in retinal disorders? A biotech’s answer shines in PhIIb
ENDPOINT NEWS By Amber Tong – Editor By the time the FDA approved Luxturna — the pioneering gene therapy for an inherited retinal disease — […]
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidenceof potential benefit in patients as an investigational treatment for retinitis pigmentosa […]
jCyte Inc. Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting
July 7th, 2020 NEWPORT BEACH, Calif.–(BUSINESS WIRE)– jCyte Inc., a biotech company dedicated to preserving andrestoring vision in patients with retinitis pigmentosa and other degenerative […]
jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicians
NEWPORT BEACH, Calif.–(BUSINESS WIRE)– jCyte Inc., a biotech company dedicated to improving thelives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory […]
UCI Startup Company jCyte Partners with Santen Pharmaceutical
UCI Beall Applied Innovation June 4, 2020 By Ethan Perez UCI company jCyte, Inc. has formalized an exclusive licensing contract with Japanese pharmaceutical company Santen Pharmaceutical. jCyte, founded by Dr. […]
Santen Inks $252M License to jCyte Ocular Cell Therapy
BioWorld Santen inks $252M license to Jcyte ocular cell therapy May 8, 2020 By Michael Fitzhugh Keen to address a rare vision-limiting disorder endured […]
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical jCyte to receive up to $252 million, […]